Harbour BioMed (02142.HK)

Executive Summary

Harbour BioMed is a global biopharmaceutical company specializing in the discovery and development of novel antibody therapeutics for immunology, oncology, and other diseases. Leveraging its proprietary fully human antibody technology platforms, including the H2L2 and HCAb platforms, the company has built a differentiated pipeline of candidate drugs and established strategic collaborations with leading pharmaceutical partners such as AstraZeneca and CStone Pharmaceuticals. Listed on the Hong Kong Stock Exchange (02142.HK), Harbour BioMed is positioned to capitalize on its robust platform capabilities and global partnerships to advance its pipeline towards clinical development. The company's focus on innovative biologics and its pre-clinical stage present both opportunities and risks for investors. In 2025, Harbour BioMed made progress in advancing its pipeline, with several candidates approaching IND-enabling studies. The company continues to expand its collaboration network, seeking co-development and licensing opportunities to accelerate drug development and share risks. With a strong cash position and a management team experienced in antibody discovery, Harbour BioMed aims to transition into a clinical-stage company within the next year. Key upcoming milestones include the initiation of first-in-human trials for lead candidates and potential new partnership announcements that could validate its technology platform and provide near-term value catalysts.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase I trial for lead oncology candidate50% success
• 2026Expansion of strategic collaboration with a top pharmaceutical company60% success
• Q3 2026Presentation of preclinical data for immunology candidate at major medical conference70% success